Could Early-Stage breast cancer patients skip chemo? new trial aims to find out
NCT ID NCT07213206
First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 23 times
Summary
This study tests whether a combination of hormone therapy, a CDK4/6 inhibitor, and anti-HER2 drugs can replace chemotherapy for women with a specific type of early-stage breast cancer (HR-positive, HER2-positive, lymph node-negative). About 1,500 participants will be randomly assigned to either the chemo-free regimen or standard chemo plus anti-HER2 therapy. The goal is to see if the new approach is as effective at preventing cancer from coming back while reducing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.